Opioid toxicity

Contents

Overview

Opioid toxicity is a major cause of drug-related death in the UK and globally, driven by prescription opioid misuse, recreational heroin use, and the emergence of synthetic opioids of extreme potency. The clinical presentation is highly recognisable — the opioid toxidrome — and responds to specific pharmacological reversal with naloxone. Management in the ICU addresses both the immediate emergency and the underlying factors contributing to toxicity.

Opioid Pharmacology

Opioids act at mu (μ), delta (δ), and kappa (κ) opioid receptors in the CNS, periphery, and enteric nervous system. Most clinically important effects — analgesia, sedation, euphoria, respiratory depression, and constipation — are mediated predominantly via mu receptors.

Respiratory depression is the life-threatening consequence of opioid overdose. Mu receptors in the brainstem respiratory centres reduce the responsiveness of these centres to carbon dioxide, decreasing respiratory rate and tidal volume. The hypercapnic drive to breathe is suppressed; hypoxic drive is preserved but overwhelmed.

Commonly Implicated Opioids

Short-acting: heroin (diacetylmorphine), morphine, oxycodone, fentanyl, alfentanil

Long-acting: methadone (half-life 24–60 hours), buprenorphine (partial mu agonist + kappa antagonist; high receptor affinity; long duration)

Synthetic ultra-potent opioids: fentanyl analogues (carfentanil, acetylfentanyl), nitazenes — up to 10,000× more potent than morphine; may not respond to standard naloxone doses; increasingly implicated in UK overdose deaths

Modified-release preparations: oxycodone MR, morphine SR, buprenorphine patches — prolonged toxicity, requiring extended observation and repeated naloxone

Tramadol: weak opioid agonist; also inhibits noradrenaline and serotonin reuptake. Toxicity causes respiratory depression, seizures (lower seizure threshold than other opioids), and serotonin syndrome-like features.

Clinical Features of Opioid Toxicity

The opioid toxidrome:

  • Miosis (pinpoint pupils): characteristic. Mediated by Edinger-Westphal nucleus stimulation via mu receptors. Note: hypoxia may cause pupillary dilatation despite opioid effect; mixed toxidromes (opioid + sympathomimetic) may give normal or dilated pupils.
  • Reduced consciousness: ranging from drowsiness to deep coma. Glasgow Coma Scale reduction.
  • Respiratory depression: reduced respiratory rate (<12/min), shallow breathing, irregular respiration, apnoea. The primary cause of death.

Additional features: bradycardia, hypotension (particularly with methadone, which also blocks HERG potassium channels — prolonged QT, torsades de pointes), hypothermia, pulmonary oedema (non-cardiogenic — from hypoxia and aspiration), bowel ileus.

Causes and Risk Factors

Recreational overdose: Deliberate misuse, accidental overdose from unknown drug purity (including contamination with synthetic fentanyl analogues), use after period of abstinence (reduced tolerance).

Prescription opioids: Accumulation in renal or hepatic impairment (active metabolites), drug interactions (sedatives, benzodiazepines, alcohol), modified-release overdose, patient self-administration errors.

ICU opioid infusions: Inadvertent bolus, pump errors, accidental residual dose in IV line, failure to account for context-sensitive half-time in prolonged infusion.

Buprenorphine/methadone: High-dose formulations in opioid substitution therapy; toxicity in co-ingestion with benzodiazepines or alcohol (the most common combination seen in overdose deaths).

Risk factors for fatal opioid overdose: Male sex, older age, concomitant CNS depressant use (benzodiazepines, alcohol, Z-drugs, gabapentinoids), recent abstinence (prison release, detox), respiratory disease (COPD, OSA), renal impairment.

Management

Immediate Priorities

Airway, Breathing, Circulation: The unconscious patient with respiratory depression requires immediate airway management. Jaw thrust and nasopharyngeal airway. Assisted ventilation with bag-mask. Prepare for endotracheal intubation if the patient cannot be adequately ventilated or does not respond to naloxone.

Supplemental oxygen: High-flow oxygen via non-rebreather mask. Monitor SpO2 and respiratory rate.

Position: Recovery position if unconscious and breathing.

Investigations

Blood gas (hypercapnia, hypoxaemia), blood glucose (hypoglycaemia may co-exist), ECG (QTc if methadone or tramadol), paracetamol level (co-ingestion is common), full toxicology screen (urine immunoassay, serum screen in severe cases).

Naloxone

Naloxone is a competitive opioid receptor antagonist with high affinity for mu receptors and no intrinsic agonist activity.

Onset: 2–3 minutes IV; 5–10 minutes IM or SC.
Duration: 30–90 minutes (typically shorter than the duration of most opioids).

Dosing:

  • Respiratory depression with spontaneous breathing: 0.1–0.4 mg IV, titrated in 0.1 mg increments to achieve adequate respiratory rate without precipitating acute withdrawal.
  • Apnoea or severe respiratory depression: 0.4–2 mg IV bolus; repeat every 2 minutes until respiratory rate is adequate. Maximum initial dose 10 mg if no response (consider alternative diagnosis or ultra-potent opioid).
  • IM: 0.4–0.8 mg (useful before IV access secured).
  • Intranasal: 1.8–2 mg (Nyxoid/Prenoxad intranasal sprays for community use by bystanders or first responders).

Re-narcotisation: Because naloxone's duration is shorter than most opioids, re-narcotisation occurs when naloxone wears off. This is particularly important with:

  • Methadone (half-life 24–60 hours)
  • Modified-release opioids
  • Buprenorphine (require high-dose naloxone — 2–10 mg)
  • Synthetic fentanyl analogues (may require very high naloxone doses or infusion)

Naloxone infusion: For long-acting opioids or re-narcotisation risk, a continuous infusion is appropriate: two-thirds of the effective bolus dose per hour, titrated.

Precipitating opioid withdrawal: In opioid-dependent patients, naloxone precipitates acute withdrawal — agitation, hypertension, tachycardia, vomiting, diarrhoea, and seizures in severe cases. Titrate naloxone to restore adequate ventilation, not to full reversal. The aim is a respiratory rate of 12–15, not full wakefulness.

Opioid Toxicity in the ICU

Several ICU-specific scenarios deserve attention:

Iatrogenic opioid toxicity in sedated patients: Context-sensitive half-time means that after prolonged opioid infusion, the drug takes much longer to clear than after a bolus. Patients who have been on fentanyl or alfentanil infusions for days may take hours to days to clear after stopping the infusion. Diagnosis is clinical — miosis and respiratory depression persisting after stopping infusion.

Accumulation in renal impairment: Morphine-6-glucuronide (active metabolite of morphine) accumulates in CKD, causing prolonged sedation and respiratory depression. Fentanyl and alfentanil are safer in renal impairment.

Opioid tolerance and hyperalgesia: Patients on long-term opioids or high-dose ICU opioids may develop tolerance (requiring higher doses for the same effect) and opioid-induced hyperalgesia (paradoxical increased pain sensitivity). Dose escalation may worsen hyperalgesia. Strategies include multimodal analgesia, ketamine, and opioid rotation.

Difficult-to-reverse toxicity: Buprenorphine's very high receptor affinity and partial agonism make it difficult to reverse with standard naloxone doses. High-dose naloxone (5–10 mg bolus, then infusion) or ventilatory support while buprenorphine wears off may be required.

Viva Questions

What is the opioid toxidrome and how do you manage it acutely?

The opioid toxidrome is the characteristic clinical syndrome of opioid excess: reduced consciousness, respiratory depression (slow, shallow, or absent respirations), and miosis. The combination of all three is highly specific for opioid toxicity, though mixed poisonings may alter the picture — hypoxia can dilate pupils, and co-ingested stimulants may increase heart rate. Immediate management follows ABCDE principles. The airway must be protected — jaw thrust and airway adjuncts first; intubation if the patient cannot be adequately ventilated or if airway reflexes are absent. High-flow oxygen is given. Naloxone is administered IV in titrated increments of 0.1–0.4 mg until respiratory rate improves — not to achieve full wakefulness in opioid-dependent patients, to avoid precipitating acute withdrawal. Blood glucose should be measured as hypoglycaemia may cause or contribute to unconsciousness. The patient must be observed until the toxidrome has fully resolved and the duration of the opioid's action has been outlasted. Re-narcotisation is a key risk — particularly with methadone, modified-release formulations, and synthetic fentanyl analogues — and requires either repeat bolus doses or a naloxone infusion.

What are the risks of naloxone in the emergency management of opioid overdose?

The principal risk of naloxone is precipitating acute opioid withdrawal in opioid-dependent patients. Withdrawal manifests as agitation, vomiting, diarrhoea, tachycardia, hypertension, diaphoresis, and in severe cases, seizures. These effects are particularly dangerous in patients with underlying cardiovascular disease. The solution is careful titration — using small incremental doses (0.1 mg IV) sufficient to restore adequate ventilation, not to achieve full reversal. In patients with unknown opioid dependence status, a pragmatic approach is to accept a respiratory rate of 12–15 breaths per minute as the endpoint, rather than full arousal. A second risk is re-narcotisation: naloxone has a shorter half-life (30–90 minutes) than most opioids. When the naloxone wears off, respiratory depression may return, particularly with long-acting opioids (methadone, modified-release formulations) or synthetic fentanyl analogues. All patients who have received naloxone must be observed for re-narcotisation for a minimum of 4–6 hours, and for longer when long-acting opioids are involved. A continuous naloxone infusion (two-thirds of the effective bolus per hour) mitigates this risk.

How does opioid toxicity differ in a critically ill patient on a fentanyl infusion from a patient presenting with heroin overdose?

The clinical presentation is similar — respiratory depression and reduced consciousness with miosis — but the context and management differ substantially. In the heroin overdose, the drug is typically short-acting (heroin is rapidly hydrolysed to morphine), making naloxone effective and re-narcotisation relatively brief. The patient may be relatively young and otherwise healthy, making intubation a temporising measure while the drug clears. In a critically ill patient who has been on a fentanyl infusion for days, the pharmacokinetics are profoundly altered by context-sensitive half-time — fentanyl has accumulated in peripheral tissues (fat, muscle) and will be released slowly over hours to days. The "half-life" of fentanyl in this context is many hours rather than the minutes seen after a single bolus. Naloxone will temporarily reverse the sedation but re-narcotisation will occur within 30–90 minutes, potentially requiring repeated boluses or an infusion. Concurrent medications — propofol, benzodiazepines, alpha-2 agonists — also contribute to the sedated state and may not respond to naloxone. In this scenario, a controlled reduction of the opioid infusion rate is preferable to abrupt reversal. If reversal is clinically necessary (e.g., to assess neurological function), careful titration with a naloxone infusion is more appropriate than large boluses.